In addition to this underlying mechanism, it is clinically relevant that DNA2 overexpression can be driven by mutp53 (Fig. 1D and E) to gain survival advantage, and is frequently found in cancer, particularly in ovarian cancer (Supplementary Fig. S2). This evidence concerns the gene DNA2 and ovarian carcinoma.